Complete Research Guide

Open each section for the available evidence. Gaps are stated rather than inferred.

Overview

Klotho (Soluble α-Klotho) is listed as longevity protein (investigational).

•Healthy-aging (longevity) research
•Memory and brain-health research
•Kidney and blood-vessel health research
•Research-market and clinic interest for cognition
•Studied as a blood marker of aging and kidney disease

Regulatory status: Not FDA-approved and not in human clinical trials as a therapy as of this review. Products sold online as "Klotho" or "Klotho peptide" are unregulated; a full recombinant protein is difficult to make and their identity is unverified. Not a dietary supplement..

Structure & Properties

Compound: Klotho (Soluble α-Klotho); also known as Klotho, alpha-Klotho, α-Klotho, s-Klotho, Soluble Klotho, KL protein, longevity protein.

Pharmacologic class: Longevity Protein (investigational).

Known delivery routes: Subcutaneous (animal studies only), Gene therapy (experimental).

Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.

How It Works

Klotho is a large protein (about 130 kDa, over 1,000 amino acids — far bigger than a typical peptide) made mainly in the kidney and in a brain area that produces spinal fluid. One form sits on cell surfaces and partners with the hormone FGF23 to control phosphate and vitamin D. A shed, soluble form circulates in blood and acts like a hormone: it dampens insulin/IGF-1 and Wnt signaling, reduces oxidative stress, protects blood vessels from calcium build-up, and, in animals, boosts NMDA-receptor signaling linked to learning. Blood levels fall with age and in chronic kidney disease.

•Extended lifespan in mice with extra Klotho (animal data)
•Improved memory after a single dose in aged mice and monkeys
•Protects kidneys and blood vessels from calcium damage (animal data)
•Higher natural levels linked to healthier aging in people (observational)

Human Research

Evidence grade: Pre-clinical / Observational

Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.

Laboratory Research

Strong animal evidence: mice lacking Klotho age rapidly, and mice with extra Klotho live about 20–30% longer. A single Klotho injection improved memory in aged mice and in older rhesus monkeys (2023). In people, evidence is observational only — lower blood Klotho is linked to kidney disease, frailty and higher death risk, and a common gene variant (KL-VS) is linked to better cognition.

Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.

Processing & Interactions

Timing and exposure

No studied schedule — Klotho has not been given to people as a treatment.

Potential interactions and combinations to avoid

•Chronic kidney disease or phosphate disorders without specialist input
•Active or suspected cancer
•Unverified research-market products

Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.

Safety & Precautions

Known or reported risks

•No human safety data for Klotho given as a product
•Monkey study showed memory benefit at low doses but not at higher doses
•May disturb phosphate, calcium and vitamin D balance
•Immune reaction possible to a large foreign-made protein
•Research-market products — identity, purity and sterility unverified

Contraindications

•Chronic kidney disease or mineral/phosphate disorders (discuss with nephrologist)
•Active cancer or history of cancer (growth-signaling effects not understood in people)
•Pregnancy or breastfeeding
•Under 18 years of age
•Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
•Active or untreated diabetic retinopathy
•Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
•Untreated hypothyroidism or uncorrected adrenal insufficiency
•Acromegaly, pituitary adenoma, or intracranial hypertension
•Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
•Critical illness after acute surgery, trauma, or respiratory failure
•Severe obstructive sleep apnea (may worsen with soft-tissue growth)
•Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
•Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
•Inability to maintain sterile technique or safe sharps disposal
•Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
•Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
•Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
•Known hypersensitivity or prior reaction to this compound or any excipient/diluent
•Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
•Children and adolescents with open growth plates (unless under specialist endocrine care)
•Active or recently treated malignancy without oncology clearance
•Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision

Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.

Administration & Studied Formulations

Reference range: No human dose exists. There are no published human trials of Klotho given as a treatment; animal and monkey studies used single low injections of a recombinant protein.

Frequency: Not established

Cycling: No cycle exists — Klotho has not been tested as a treatment in people.

Subcutaneous (animal studies)

Not established in people.

Research only — single injections of recombinant protein in animals. No human technique exists.

Monkey data suggest low doses helped memory while higher doses did not.

Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.

Applications & Related Therapies

Potentially complementary measures

•Regular exercise (linked to higher natural Klotho levels)
•Kidney-friendly blood-pressure and blood-sugar care
•Adequate sleep

Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.

Educational only. Human evidence is observational; treatment data come from animals and monkeys.

Cases, Considerations & Ethics

Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.

Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.

Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.

What is Klotho (Soluble α-Klotho)?

In plain words

Klotho is a natural "longevity protein" made mostly by the kidneys. It helps control minerals like phosphate and protects blood vessels and the brain. Levels drop as we age. Mice with extra Klotho live longer, and one dose sharpened memory in older monkeys, but it has never been tested as a treatment in people.

Technical definition

α-Klotho is a single-pass transmembrane glycoprotein (~130 kDa) expressed mainly in the renal distal tubule and choroid plexus. Membrane Klotho is an obligate co-receptor for FGF23 in phosphate and vitamin D regulation; its ectodomain is shed by ADAM10/17 to form soluble Klotho, which acts as a circulating hormone that modulates insulin/IGF-1, Wnt and TGF-β signaling and enhances NMDA-receptor function in rodent models. It is an investigational longevity protein, not FDA-approved, with no human interventional trials.

Function

Primary

Healthy-aging (longevity) research · Memory and brain-health research · Kidney and blood-vessel health research

Secondary

Research-market and clinic interest for cognition · Studied as a blood marker of aging and kidney disease

Mechanism

Klotho is a large protein (about 130 kDa, over 1,000 amino acids — far bigger than a typical peptide) made mainly in the kidney and in a brain area that produces spinal fluid. One form sits on cell surfaces and partners with the hormone FGF23 to control phosphate and vitamin D. A shed, soluble form circulates in blood and acts like a hormone: it dampens insulin/IGF-1 and Wnt signaling, reduces oxidative stress, protects blood vessels from calcium build-up, and, in animals, boosts NMDA-receptor signaling linked to learning. Blood levels fall with age and in chronic kidney disease.

Evidence

Pre-clinical / Observational

Research

Strong animal evidence: mice lacking Klotho age rapidly, and mice with extra Klotho live about 20–30% longer. A single Klotho injection improved memory in aged mice and in older rhesus monkeys (2023). In people, evidence is observational only — lower blood Klotho is linked to kidney disease, frailty and higher death risk, and a common gene variant (KL-VS) is linked to better cognition.

Dosing

Range

No human dose exists. There are no published human trials of Klotho given as a treatment; animal and monkey studies used single low injections of a recombinant protein.

Frequency

Not established

Route

Subcutaneous (animal studies only) · Gene therapy (experimental)

Recommended Time of Day

Not established — no human treatment studies.

See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.

Administration & Technique

Subcutaneous (animal studies)

Not established in people.

DeviceResearch only — single injections of recombinant protein in animals.

TechniqueNo human technique exists.

Monkey data suggest low doses helped memory while higher doses did not.

Injection & Application Sites

Front

Back

Subcutaneous (animal studies)

Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.

Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.

Cycling

No cycle exists — Klotho has not been tested as a treatment in people.

Timing & Interactions

When to take

No studied schedule — Klotho has not been given to people as a treatment.

Do not combine with

·Chronic kidney disease or phosphate disorders without specialist input
·Active or suspected cancer
·Unverified research-market products

Complements

·Regular exercise (linked to higher natural Klotho levels)
·Kidney-friendly blood-pressure and blood-sugar care
·Adequate sleep

Notes

Educational only. Human evidence is observational; treatment data come from animals and monkeys.

Storage & Reconstitution

Powder (Pre-Reconstitution)

Lyophilized protein: freeze at –20°C or colder, protected from light; avoid repeated thawing.

After Reconstitution

Refrigerate 2–8°C and use promptly; large proteins lose activity quickly in solution.

Notes

Research-market products are unverified — identity and activity cannot be confirmed without testing.

Full BAC water & reconstitution guide →How to read a COA →

Reconstitution Calculator

Peptide in vial (mg)

BAC water added (mL)

Desired dose (mcg)

Concentration

2.50 mg/mL

Volume per dose

0.100 mL

Insulin syringe

10.0 units (U-100)

1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.

Your Notes

Sign in to save personal notes on Klotho (Soluble α-Klotho) and sync them to Vial Lab.

Benefits

·Extended lifespan in mice with extra Klotho (animal data)
·Improved memory after a single dose in aged mice and monkeys
·Protects kidneys and blood vessels from calcium damage (animal data)
·Higher natural levels linked to healthier aging in people (observational)

Risks

·No human safety data for Klotho given as a product
·Monkey study showed memory benefit at low doses but not at higher doses
·May disturb phosphate, calcium and vitamin D balance
·Immune reaction possible to a large foreign-made protein
·Research-market products — identity, purity and sterility unverified

Contraindications

·Chronic kidney disease or mineral/phosphate disorders (discuss with nephrologist)
·Active cancer or history of cancer (growth-signaling effects not understood in people)
·Pregnancy or breastfeeding
·Under 18 years of age
·Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
·Active or untreated diabetic retinopathy
·Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
·Untreated hypothyroidism or uncorrected adrenal insufficiency
·Acromegaly, pituitary adenoma, or intracranial hypertension
·Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
·Critical illness after acute surgery, trauma, or respiratory failure
·Severe obstructive sleep apnea (may worsen with soft-tissue growth)
·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
·Inability to maintain sterile technique or safe sharps disposal
·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
·Children and adolescents with open growth plates (unless under specialist endocrine care)
·Active or recently treated malignancy without oncology clearance
·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision

Regulatory

Not FDA-approved and not in human clinical trials as a therapy as of this review. Products sold online as "Klotho" or "Klotho peptide" are unregulated; a full recombinant protein is difficult to make and their identity is unverified. Not a dietary supplement.

Veterinary Use (Pets)

No established veterinary protocol for Klotho (Soluble α-Klotho). Consult a licensed veterinarian before considering off-label use in any species.

Full veterinary reference →

Functional Groups

Longevity Cognitive Function

Cited Works

Tap any study to open the published work.